AbbVie: acquisition of Celsius for $250 million

(CercleFinance.com) - On Thursday, AbbVie announced the acquisition of US biotech company Celsius Therapeutics for $250 million in cash.


The Chicago-based pharmaceutical group says the deal will give it access to the drug candidate CEL383, an antibody currently in Phase 1 clinical trial for the treatment of inflammatory bowel disease.

The compound belongs to the class of antibodies acting on TREM-1, a membrane receptor mainly expressed by myeloid cells that amplifies inflammation.

Copyright (c) 2024 CercleFinance.com. All rights reserved.